Arca
Skip to content
Tools
Tools

Diffuse scleroderma

Drug research and approvals for diffuse scleroderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 145 studies of diffuse scleroderma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 145
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 145 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

2 in phase 3, 13 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Lenabasum
Phase 3
Sildenafil
Phase 3 Phosphodiesterase 5A inhibitor
Brentuximab vedotin
Phase 2 Tubulin inhibitor
Mycophenolate mofetil
Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Human immunoglobulin g
Phase 2 Replacement therapy, immunomodulatory effects
Abatacept
Phase 2 T-lymphocyte activation antigen CD86 inhibitor
Belumosudil
Phase 2 Rho-associated protein kinase 2 inhibitor
Methoxsalen
Phase 2 DNA inhibitor
Acetylcysteine
Phase 2 Glutathione precursor
Lanifibranor
Phase 2 Peroxisome proliferator-activated receptor agonist
Ianalumab
Phase 2 Tumor necrosis factor receptor superfamily member 13C binding agent
Dersimelagon
Phase 2 Melanocortin receptor 1 agonist
Rilonacept
Phase 1 Interleukin-1 beta inhibitor
Teprotumumab
Phase 1 Insulin-like growth factor I receptor antagonist
Fresolimumab
Phase 1 Transforming growth factor beta-1 inhibitor
AVID-200
Phase 1

How Its Trials Ended

561 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 126 whose ending is known, 37% met their primary endpoint, 12% missed it and 52% stopped early.

  • Completed, result not reported20336%
  • Ongoing15227%
  • Status unknown8014%
  • Met its primary endpoint468%
  • Stopped: other or unclear326%
  • Stopped: enrollment or feasibility163%
  • Missed its primary endpoint153%
  • Stopped: sponsor or business decision81%
  • Stopped: lack of efficacy61%
  • Stopped: safety20%
  • Stopped: funding10%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.